Impact BioMedical (IBO) Registration Filing summary

Company overview and business model

• Operates as a holding company focused on drug discovery, wellness, and biomedical IP, primarily through majority-owned subsidiary Global BioLife, Inc.

• Develops and patents technologies in biopharmaceuticals, sugar substitutes, and functional fragrances, leveraging licensing, co-development, and joint ventures.

• Principal subsidiaries include Impact BioLife Science, Global Biomedical, Global BioLife, and Sweet Sense, with varying ownership stakes.

• Business model centers on out-licensing, milestone, and royalty payments, with potential for direct sales and commercialization partnerships.

• Key technologies: Linebacker (therapeutic platform), Laetose (sugar substitute), 3F (functional fragrance), and Equivir (antiviral blend).

Financial performance and metrics

• For the three months ended March 31, 2024: net loss of $998,000, compared to $849,000 in the prior year period.

• As of March 31, 2024: cash of $2,000, total assets of $44.4M, total liabilities of $17.1M, and stockholders' equity of $27.3M.

• For the year ended December 31, 2023: net loss of $4.4M, improved from $7.3M in 2022, primarily due to prior year investment impairment.

• No revenue in 2023; prior year revenue of $50,000 from licensing milestone payments.

• Ongoing operating losses and negative cash flows raise substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• Net proceeds from IPO (estimated $5.1M) to be used for R&D (approx. 20%), licensing/commercialization, working capital, and general corporate purposes.

• Proceeds may also be used for debt repayment and funding offering costs.

• Actual allocation may change based on operating needs and cash position.